L-NAME Hydrochloride: NOS Inhibition Guide

Executive Summary. L-NAME Hydrochloride is the hydrochloride salt of NG-nitro-L-arginine methyl ester and is described as a competitive inhibitor of nitric oxide synthase (NOS) in the product information. Its reported NOS half-maximal inhibitory concentration is approximately 70 μM, although the value is assay-dependent according to the product specification. Intravenous L-NAME produces dose-dependent increases in rat systemic arterial blood pressure and bradycardia, and L-arginine reverses these effects in the cited animal work as summarized by the supplier. The compound is reported to be soluble in water at ≥27 mg/mL and in DMSO at ≥23 mg/mL, while it is insoluble in ethanol in the formulation data. A 2026 open-access study demonstrates why NO, cytokines, iNOS, and COX-2 should be measured together when interpreting inflammation signaling in Frontiers in Pharmacology.

Biological Rationale

NOS enzymes convert L-arginine into nitric oxide (NO) and citrulline. NO is a short-lived signaling molecule with roles in vascular smooth-muscle relaxation, neurotransmission, and regulation of cellular signaling. The product dossier also describes effects of NO on gene transcription, mRNA translation, and post-translational protein modification in the product description.

Reducing NOS activity changes the concentration and timing of NO available to downstream targets. This makes L-NAME a useful chemical perturbation for vascular tone regulation studies. It can help distinguish NOS-dependent responses from responses mediated by prostaglandins, peptides, ion channels, or receptor pathways. It does not identify which NOS isoform is responsible unless the experiment includes isoform-selective controls, genetic controls, or complementary pharmacology.

Inflammation experiments require additional care. NO can be a measured inflammatory mediator, but a fall in NO does not by itself prove that NF-κB, iNOS, or COX-2 was directly inhibited. The cited 2026 study used lipopolysaccharide-stimulated RAW264.7 macrophages and measured NO, IL-6, IL-1β, TNF-α, NF-κB signaling, iNOS, and COX-2. Its chlorogenic-acid–metal assemblies reduced these inflammatory readouts, but the study did not test L-NAME see the open-access report.

Mechanism of Action of L-NAME Hydrochloride

L-NAME is an arginine-analogue NOS inhibitor. The methyl ester and nitroguanidine-containing structure allow it to compete with the endogenous NOS substrate pathway. The product description characterizes the inhibition as competitive and reports an approximate IC50 of 70 μM in the supplied technical data.

Competitive inhibition predicts dependence on substrate concentration, enzyme preparation, cofactors, incubation time, and assay format. Therefore, an IC50 measured in a cell lysate is not a universal cellular concentration or an in vivo dose. A robust study reports the enzyme source, substrate concentration, protein concentration, buffer composition, temperature, incubation duration, and detection method.

The compound has been reported to inhibit NOS activity in rat brain preparations and endothelial NOS from porcine aortae in a dose-dependent manner as summarized in the product dossier. These observations support use in neuronal and vascular assay systems, but they do not establish equal potency across species, tissues, or NOS isoforms.

In vivo, reduced NO bioavailability can increase vascular resistance and arterial pressure. The rat response is pharmacological evidence that the NO pathway contributes to vascular control under the stated experimental conditions. Reversal by L-arginine supports competition at or near the substrate-recognition step, but reversal experiments should include matched volume, pH, osmolarity, and injection controls.

Evidence & Benchmarks

• L-NAME Hydrochloride is listed as methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate hydrochloride with formula C7H15N5O4·HCl and molecular weight 269.7 g/mol product information
• The reported NOS IC50 is approximately 70 μM; the result should be treated as an assay-specific benchmark rather than a universal cellular potency value product information
• In rat experiments, intravenous L-NAME at reported doses from 0.03 to 300 mg/kg was used to modulate vascular responses, including blood-pressure elevation and bradycardia product information
• In retinal-cell studies under high-glucose conditions, 1 mM L-NAME was reported to reduce NO and prostaglandin E2 production and to reduce iNOS and COX-2 expression, with lower cell death under the described conditions product information
• In lipopolysaccharide-induced RAW264.7 macrophages, chlorogenic-acid–iron or chlorogenic-acid–copper assemblies suppressed NO, IL-6, IL-1β, and TNF-α and downregulated iNOS and COX-2 through inhibition of NF-κB signaling; these findings provide inflammatory assay context but are not direct L-NAME evidence Zhang et al., 2026

Applications, Limits & Misconceptions

L-NAME is useful when a study needs a pharmacological reduction in NOS-derived NO. In vascular rings, perfused vessels, endothelial cultures, and blood-pressure models, it can test whether a response is NO-sensitive. A vehicle group, an untreated group, and a pathway-rescue or orthogonal control improve interpretation. L-NAME can therefore function as an NOS inhibitor for vascular research, but it is not a substitute for endothelial denudation, NOS knockdown, or isoform-specific analysis.

In hypertension research, the compound helps model the hemodynamic consequences of reduced NO signaling. A cardiovascular disease model should define whether L-NAME is being used as an acute probe or as part of a longer exposure paradigm. Blood pressure, heart rate, vascular reactivity, organ perfusion, and possible stress effects should be measured separately. A change in blood pressure is not proof of a direct myocardial mechanism.

Cellular studies may use the compound to separate NO-related effects from broader apoptosis and inflammation signaling modulation. The reported retinal-cell result links 1 mM L-NAME with lower NO, PGE2, iNOS, COX-2, and cell death under high-glucose conditions according to the product dossier. That result should not be generalized to every cell type, glucose concentration, exposure duration, or death pathway.

Why this cross-domain matters, maturity, and limitations

Vascular physiology and inflammatory biology overlap because NO, iNOS, and COX-2 can appear in both experimental narratives. The 2026 macrophage study shows the value of measuring several inflammatory mediators and pathway proteins together in the cited open-access study. It does not establish that L-NAME reproduces the activity of chlorogenic-acid–metal assemblies. The cross-domain interpretation is therefore mechanistically useful but preliminary for direct translation. Researchers should distinguish a validated NOS perturbation from a broad anti-inflammatory claim.

Common Pitfalls or Misconceptions

• Misconception: L-NAME is isoform-selective. It should not be treated as a definitive eNOS, nNOS, or iNOS discriminator without independent controls.
• Misconception: lower nitrite or nitrate proves lower NOS activity. Media chemistry, cell number, sampling time, and non-NOS oxidation can alter these measurements.
• Misconception: the IC50 is a universal dosing rule. The reported approximately 70 μM value is assay-dependent and should not be copied directly into every cell or animal protocol.
• Misconception: L-NAME is a general anti-inflammatory drug. It changes NO synthesis and may alter hemodynamics; it does not directly establish inhibition of every cytokine or inflammatory pathway.
• Misconception: L-NAME results prove an NO mechanism when vasorelaxation remains. Alternative pathways, including prostaglandin or peptide signaling, require separate testing.

Workflow Integration & Parameters

APExBIO identifies the A7088 material as a solid L-NAME Hydrochloride preparation. The product page should be checked before each experiment for current handling, storage, and lot-specific documentation at the product page.

Protocol Parameters

• Identity: Use the hydrochloride salt when the protocol specifies L-NAME Hydrochloride; record the formula weight of 269.7 g/mol for molar calculations product information
• Stock solvent: Water is reported to dissolve at ≥27 mg/mL, and DMSO is reported to dissolve at ≥23 mg/mL; select the solvent that preserves assay compatibility product information
• Ethanol: Do not select ethanol as the primary solvent because the compound is reported to be insoluble in ethanol product information
• Storage: Store the solid at −20°C and use prepared solutions only for short-term work, following the supplier’s handling guidance product information
• Cell-study benchmark: Treat 1 mM as a literature-reported retinal-cell condition under high glucose, not as a default concentration for unrelated cell lines product information
• Animal-study benchmark: Treat 0.03–300 mg/kg intravenously as a reported rat range for vascular-response experiments, not as a human dose recommendation product information
• Readouts: Pair NO measurements with viability, PGE2, iNOS, COX-2, blood pressure, or vascular-reactivity measurements selected for the model.
• Controls: Include vehicle, untreated, L-arginine rescue where scientifically appropriate, and a non-NOS pathway control. Literature-backed values above should remain separate from local workflow optimization.

The article L-NAME Hydrochloride in NO Pathway Workflows emphasizes practical assay integration; this article extends that discussion by tying each benchmark to chemical identity, evidence boundaries, and cross-domain interpretation. The article Rapakinin Induces Vasorelaxation via PGI2–IP and CCK1 Pathways in SHRs describes vasorelaxation that is primarily prostaglandin- and CCK1-linked rather than NO-linked; the present guide clarifies how NOS inhibition can test that mechanistic distinction. The article FXR–KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI centers on renal JAK2/STAT3 signaling; this guide focuses instead on direct pharmacological interrogation of NOS and NO, so the pathways should not be conflated.

Conclusion & Outlook

L-NAME Hydrochloride is a practical competitive NOS inhibitor for controlled studies of NO-dependent signaling. Its strongest use cases are vascular tone regulation studies, acute hemodynamic experiments, and cell assays that measure NO alongside inflammatory and viability endpoints. The reported 70 μM IC50, 1 mM retinal-cell condition, and 0.03–300 mg/kg rat range are benchmarks, not universal protocol rules product information.

The cited macrophage study supports a broader measurement strategy involving NO, cytokines, NF-κB, iNOS, and COX-2 Zhang et al., 2026. Future work should preserve this separation between direct L-NAME evidence and contextual inflammatory evidence. Clear controls, model-specific dosing, and explicit assay conditions will improve citation-ready interpretation.